Home›Stock Screener›Ganga Pharmaceuticals

Ganga Pharmaceuticals Share Price Today | Stock Price & Ganga Pharmaceuticals Share Screener

GANGAPHARM Pharmaceuticals

Track the current Ganga Pharmaceuticals share price and stock price live with TickJournal's free stock screener. Check GANGAPHARM 52-week performance for the annual price range and momentum. Use the Ganga Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Ganga Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Ganga Pharmaceuticals Market Cap ₹7.40 Cr.
GANGAPHARM P/E Ratio (TTM) 488.20
Ganga Pharmaceuticals P/B Ratio 0.95
EPS (TTM) ₹0.17
Dividend Yield -
Debt to Equity 0.16
GANGAPHARM 52 Week High -
Ganga Pharmaceuticals 52 Week Low -
Operating Margin -2.00%
Profit Margin -
GANGAPHARM Revenue (TTM) ₹2.00
EBITDA -
Net Income -
Total Assets ₹10.00
Total Equity ₹8.00

Ganga Pharmaceuticals Share Price Chart

Track the current stock price of Ganga Pharmaceuticals with an interactive chart. Analyse GANGAPHARM share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Ganga Pharmaceuticals stock quote in one place.

Ganga Pharmaceuticals Company Profile - Fundamental Screener

Screen Ganga Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GANGAPHARM shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE615T01017.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE615T01017

Ganga Pharmaceuticals Balance Sheet Screener

Screen GANGAPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹10, up from ₹9 in 2025.

Latest statistics put total assets at ₹10 and shareholder funds at ₹8, with a leverage ratio of 0.16.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 10 9 9 8 8 8 8 8 8 8
Current Assets 8 7 6 5 5 5 4 4 5 4
Fixed Assets 1 1 1 1 1 1 1 1 1 1

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 0 0 0 1 1 1 1 1 1 1
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 8 7 7 6 5 5 5 5 5 5
Share Capital 6 5 5 4 4 4 4 4 4 4
Reserves & Surplus 2 2 2 1 1 1 1 1 1 1

Ganga Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis

Screen Ganga Pharmaceuticals income statement and profit fundamentals. Analyze GANGAPHARM quarterly results. Ganga Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹2 and net profit was ₹0, equal to earnings per unit of ₹0.10, at an operating margin of -2%.

In that period expenses were ₹1, interest cost ₹0 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹3 and net profit of ₹0.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 2 3 3 3 3 3 3 3 4 3 3 3 3
Expenses 1 3 3 3 3 2 2 3 3 3 3 2 2

Operating Costs and Margins

EBITDA 0 0 0 0 0 0 0 1 1 1 1 0 0
Operating Profit % -2.00% 1.00% -4.00% 2.00% 0.00% 2.00% 1.00% 13.00% 12.00% 11.00% 10.00% 12.00% 9.00%
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0

Profit and Earnings

Profit Before Tax 0 0 0 0 0 0 0 0 0 0 0 0 0
Tax 0 0 0 0 0 0 0 0 0 0 0 0 0
Net Profit 0 0 0 0 0 0 0 0 0 0 0 0 0
EPS 0.10 0.17 0.16 0.11 0.10 0.09 0.05 0.46 0.46 0.23 0.18 0.12 0.00

Ganga Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen GANGAPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities used ₹1.

Over the same period, investing activities provided ₹0 and financing activities provided ₹1.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities -1 -1 -1 0 0 0 0 0 0 0
Investing Activities 0 1 0 1 0 0 0 0 0 1

Financing and Net Cash

Financing Activities 1 0 1 0 0 0 0 0 0 0
Net Cash Flow 0 0 0 0 0 0 0 0 0 0

Ganga Pharmaceuticals Shareholding Pattern Screener

See Ganga Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Ganga Pharmaceuticals promoter holding and ownership changes for GANGAPHARM on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 50.91%, foreign institutions 0.00%, domestic institutions 0.00% and the public 35.32%, spread across 365 shareholders.

The shareholder count was 365 in 2026-Mar, compared with 368 in 2025-Mar.

Item 2026-Mar 2025-Mar 2025-Jun 2025-Jul 2025-Sept 2024-Mar 2024-Sept 2023-Mar

Promoter Holding

Promoter Holding 50.91% 56.02% 50.91% 50.91% 50.91% 56.02% 56.02% 66.71%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 35.32% 35.07% 35.46% 35.46% 35.32% 35.40% 35.23% 31.91%
Other Holding 13.77% 8.91% 13.63% 13.63% 13.77% 8.58% 8.75% 1.38%
Shareholder Count 365 368 367 367 366 363 365 356

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Ganga Pharmaceuticals. Ganga Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Ganga Pharmaceuticals.

Ganga Pharmaceuticals Stock Index Membership - Nifty & Sensex

See which indices include Ganga Pharmaceuticals stock. Check GANGAPHARM index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Ganga Pharmaceuticals is not part of any tracked indices.
Only major market indices are tracked in our system.

Ganga Pharmaceuticals Market Events Screener - Corporate Actions

Get Ganga Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Ganga Pharmaceuticals stock events that may affect GANGAPHARM share price, along with derivatives, futures and options activity and sector gainers.

8 corporate actions are listed, the most recent entry being Annual General Meeting dated September 26, 2026, with a record date of September 26, 2026.

It is followed by Quarterly Result Announcement dated May 21, 2026 and Quarterly Result Announcement dated November 7, 2025.

Announcement Date Record Date Event Type Information Price Impact
2026-09-26 2026-09-26 Annual General Meeting NA 4.17%
2026-05-21 2026-05-21 Quarterly Result Announcement NA 0.00%
2025-11-07 2025-11-07 Quarterly Result Announcement NA 0.00%
2025-09-20 2025-09-20 Annual General Meeting NA 0.00%
2025-05-20 2025-05-20 Quarterly Result Announcement NA 0.00%
2024-11-08 2024-11-08 Quarterly Result Announcement NA 0.00%
2024-09-25 2024-09-25 Annual General Meeting NA -20.67%
2024-01-04 2024-01-04 Extraordinary General Meeting NA 88.72%

Ganga Pharmaceuticals Competitors Screener - Peer Stocks Comparison

Screen GANGAPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 441,934 36.44 61,674 12.69% 11,565 40.74
Divis Laboratories 252,421 86.51 11,067 13.95% 2,568 63.87
Torrent Pharmaceuticals 184,821 85.91 13,886 20.34% 2,138 46.50
Zydus Life Science 122,308 26.32 27,658 17.64% 5,026 66.57
Cipla 112,185 33.44 29,045 2.24% 3,870 45.42
Laurus Labs 108,603 99.70 6,868 22.01% 890 64.04
Dr Reddys Laboratories 104,092 32.05 35,059 3.90% 4,158 63.11
Mankind Pharma 103,963 48.73 14,636 14.85% 1,938 55.24
Aurobindo Pharma 98,039 26.36 34,145 5.56% 3,503 54.66
Lupin 94,940 16.99 29,039 26.75% 5,356 35.30

Ganga Pharmaceuticals Company Announcements - News & Reports Screener

Screen GANGAPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 3, 2026.

The next most recent announcements are dated October 3, 2026 and October 3, 2026.

Date Update Actions
2026-10-03 Announcement under Regulation 30 (LODR)-Change in Directorate -
2026-10-03 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-10-03 Closure of Trading Window -
2026-10-03 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-02 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-01 The Company Has Sent Letter To The Shareholder For AGM Whose Email Id Is Not Registered With RTA. -
2026-09-01 Notice Of The AGM For F.Y. 2025-26 -
2026-09-01 Reg. 34 (1) Annual Report. -
2026-09-01 Intimation For 37Th Annual General Meeting Scheduled To Be Held On Saturday September 26 2026 -
2026-07-10 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-07-09 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-05-28 Compliances-Reg.24(A)-Annual Secretarial Compliance -
2026-05-21 Appointment Of Secretarial Auditor -
2026-05-21 Appointment Of Internal Auditor -
2026-05-21 Audited Financial Results Of The Company For The Half Year And Financial Year Ended March 31 2026. -
2026-05-21 Board Meeting Outcome for Outcome Of The Board Meeting Held On May 21 2026 -
2026-05-14 Board Meeting Intimation for Board Meeting Intimation Under Regulation 29 The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-04-09 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-03-26 Closure of Trading Window -
2026-03-16 Announcement under Regulation 30 (LODR)-Newspaper Publication -

Frequently Asked Questions

How is the company valued right now?

The P/E ratio is 488.20 and the P/B ratio is 0.95, with earnings per unit of ₹0.17. Market capitalisation stands at ₹7.40 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Key statistics were last updated on October 5, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.